Dear visitor, thank you for your interest in Ovarcome! Please explore our website and our information to learn more about our organization, our programs and services, our dreams and aspirations, and how you can be an integral part of our crusade against ovarian cancer.
If you’d like to share your story, have a question for us, or have any ideas you’d like to mention to us, please complete the form below. We would love to hear from you!
Chief of Gynecologic Oncology, University of Oklahoma
This episode of Connect Ovar Coffee explores the rapidly evolving landscape of early-phase clinical trials and their role in shaping the future of ovarian cancer treatment. Dr. Debra Richardson explains how modern Phase I trials have evolved beyond simply determining safety to identifying the optimal balance between efficacy and tolerability, giving patients access to promising therapies years before they become widely available.
The conversation highlights the growing importance of:
Dr. Richardson discusses the importance of considering clinical trials earlier in a patient’s journey whenever appropriate, as they are the driving force behind progress and often provide access to tomorrow’s treatments today.
The discussion concludes with prevention and early detection, including opportunistic salpingectomy, hereditary cancer risk assessment, and ongoing screening research. Dr. Richardson leaves viewers with an optimistic outlook that the pace of scientific discovery, recent FDA approvals, and an expanding pipeline of innovative therapies are bringing the field closer to making ovarian cancer a manageable chronic disease while continuing the pursuit of a cure.
“We’re in really exciting times right now. We’re seeing more FDA approvals, more treatment options for our patients, and you’re going to see even more approvals in the coming years. Before we find a cure, my goal is for ovarian cancer to become a chronic disease, one where patients can enjoy a full quality of life while continuing to receive effective treatment. We are slowly but surely getting there.”
– Dr. Debra Richardson
In this episode of Connect Ovar Coffee, Dr. Angeles Secord, Director of Gynecologic Oncology Clinical Trials at Duke Cancer Institute, discusses how biomarkers, precision medicine, targeted therapies, and clinical trials are reshaping ovarian cancer care.
“Every time I go to clinic, my cup gets lifted up again because I see patients that are long-term survivors… That helps me know that we are Ovarcoming every day in this fight against this disease.” – Dr. Angeles Secord
The future of ovarian cancer care is increasingly driven by precision medicine. Through comprehensive biomarker testing, innovative targeted therapies, clinical trials, and personalized treatment strategies, meaningful progress continues to improve outcomes and offer renewed hope for patients and families.
This episode features Dr. Alexander Olawaiye, discussing major advances in ovarian cancer treatment, including the ROSELLA clinical trial.
Closing Message:
Stay informed, consider clinical trials, and remain hopeful as new treatments continue to emerge.
Highlights with Dr. Robert Wenham (Moffitt Cancer Center)
“Let’s Ovarcome our historical perspective and realize that things are much better now and are only going to get better in the near future.”
Chair, Department of OB-GYN | Houston Methodist Neal Cancer Center
In this episode of Connect Over Coffee, Dr. Pedro Ramirez, one of the world’s leading gynecologic oncologic surgeons, shares evidence-based insights on ovarian cancer surgery, evolving treatment strategies, and how patients can be empowered to make informed, collaborative decisions about their care.
Patient-Centered Surgical Decision-Making
Dr. Ramirez emphasizes a critical principle:
“A good surgeon knows how to operate. A great surgeon knows when not to operate.”
Surgery First vs. Chemotherapy First
Five major randomized clinical trials—including the landmark TRUST trial—demonstrate no difference in overall survival between:
However, chemotherapy first is consistently associated with fewer complications and safer outcomes. As a result, 80–85% of patients today receive chemotherapy first, a major shift from earlier practice.
Patients should ask:
Surgical Advances & De-escalation
The field is moving toward less aggressive, more precise surgery, including:
Recovery & Quality of Life
Enhanced Recovery After Surgery (ERAS) protocols are now standard at leading centers. These include:
ERAS reduces recovery time from weeks to days, improving quality of life without compromising safety
HIPEC: Use With Caution
Heated Intraperitoneal Chemotherapy (HIPEC) is not standard of care in the U.S. It may benefit a narrow group of patients undergoing interval surgery but carries higher complication risks and should only be considered at highly experienced centers
Fertility Preservation
For young patients:
Looking Ahead: 2026 and Beyond
Dr. Ramirez is optimistic about the future of ovarian cancer care that will likely witness:
Ovarian cancer is increasingly being managed as a chronic disease, allowing patients to live fuller lives while on treatment.
Dr. Ramirez’s final Message to Ovarcomers
Be informed. Ask questions. Seek second opinions when needed. Choose care teams that treat you, not just the disease. Above all, there is real hope, driven by science, collaboration, and patient empowerment.
Transforming Treatment in Ovarian Cancer: Breakthroughs offering Hope
Guest: Dr. Premal Thaker
Director of Gynecologic Oncology at Washington University School of Medicine in St. Louis
Antibody-Drug Conjugates (ADCs)
Glucocorticoid Antagonists
Breakthrough Clinical Trials
Keynote B96 Trial
Ovation 3 Trial (under Dr. Thaker’s leadership)
Combination & Maintenance Therapies
Personalized Treatment by Biomarker
Future of ADCs
Biomarkers & Testing
Importance of NGS (Next Generation Sequencing)
Emerging Biomarkers
Disparities & Global Challenges
Key Concepts Explained<
Other Scientific Highlights
Research & Clinical Trials: The Future
“Ovarian cancer care is entering a transformative era—where science is smarter, treatments are more targeted, and every woman deserves access to that hope.”
Dr. Thaker emphasizes that we are witnessing major progress in ovarian cancer treatment, with innovations like antibody-drug conjugates, biomarker-driven therapies, and clinical trials that are finally showing survival benefits.
But she’s also clear: these advances must reach everyone.
That means:
Topic: Breaking the Code: Disrupting Cellular Communication in Ovarcoming Ovarian Cancer
Guest: Dr. Emil Lou
Medical Oncologist, University of Minnesota Medical School
Ovarian cancer symptoms often go undetected or are misunderstood, leading to late-stage diagnosis.
Dr. Lou emphasizes the need for better education in medical training and encourages mainstreaming ovarian cancer in curricula.
A core message is that we must listen to the voice of the patients. Many patients feel dismissed when reporting symptoms. This needs to change.
Dr. Lou shares deeply emotional reflections on the psychological and spiritual resilience he sees in his patients. He draws strength from their courage and celebrates organizations like Ovarcome for creating empowering spaces.
– To patients: You are seen, heard, and valued. Never doubt your voice.
– To doctors & researchers: Let empathy and listening guide your science.
– To the public: Support ovarian cancer education and advocacy. It can save lives.
“Ovarian cancer is not just a disease. It’s a deeply human experience that deserves more attention, research, and heart.”
Topic: Latest Advances in Gynecologic Cancers
Guest: Dr. Brian Slomovitz,
Director of Gynecologic Oncology, Mount Sinai Medical Center of Florida
Seek second opinions and the best possible care early. The timing of enrolment in Clinical Trials matters. Do not delay in seeking options available to you.
Hope is growing. Keep Ovarcoming!
Topic: MIF of SIX in Ovarcoming Ovarian Cancer
Guest: Dr. Lorenzo Cohen, Director of Integrative Medicine at MD Anderson Cancer Center & Alison Jefferies, Board-Certified Wellness Coach, Educator, and Author
Foundation for all behavior change. Enhances biological resilience and reduces stress. Guests encouraged to seek support from Ovarcome, hospitals, online networks, and non-family members.
Chronic stress fuels cancer progression. Tools include yoga, CBT, meditation, tai chi, breathwork. Daily and consistent practice is essential.
Adequate sleep improves immune function, metabolism, and cognition. Guests emphasize sleep routines, reducing light exposure, and managing caffeine/alcohol intake.
Reduces treatment side effects, enhances mood, boosts immunity. Cardio, resistance training, stretching, and reduced sedentary behavior are key.
Guests highlight a plant-centered Mediterranean diet, combining animal protein in moderation and plant protein in abundance. Focus is on fiber and gut health, reduced processed foods and over-reliance on probiotics.
Limit exposure to toxins and digital overstimulation. Use tools like EWG.org to identify safe personal and household products.
Topic: Granulosa Cell Tumors, What You Should Know
Guest: Dr. Tyler Hillman, Associate Professor, University of California, San Diego
“Be involved. Stay connected. You are not alone.”
Topic: Innovations in Ovarian and Gynecologic Cancers
Guest: Dr. Elizabeth Swisher, Professor & Director of Gynecologic Oncology, Fred Hutch
Topic: Oncology Nutrition, Lifestyle Wellness, and Cancer Recovery
Guest: Dr. Renee Stubbins, Oncology Dietitian, Houston Methodist
“Eat your fruits and vegetables, stay active, and get lots of rest and sunlight.”
Topic: Compassionate Cancer Care, Survivorship, and Innovations in Treatment
Guest: Dr. Erin Stevens, Surgical Oncologist, Prevea Health
Topic: Surgical Advances, Prevention, and Personalized Care in Gynecologic Cancers
Guest: Dr. Kara Long, Surgeon & Oncologist, Memorial Sloan Kettering Cancer Center
Surgical Innovations
Topic: Ovarian Cancer Recurrence, Innovation, and Patient Support
Guest: Dr. Marta Crispens, Director of Gyn Oncology, Vanderbilt Ingram Cancer Center
Ovarian Cancer is Heterogeneous: High-grade serous carcinoma differs from low-grade; requires personalized treatment.
Recurrence Causes:
Drug Resistance Factors:
Immunotherapy Challenges:
Emerging Solutions:
Targeted Therapies:
Desensitization for Drug Allergies:
PARP Inhibitors:
Side Effect Management:
Emotional Navigation:
Support Clinical Trials:
Advocacy:
“More isn’t always better—but balance is.”— Dr. Marta Crispens
Topic: CA125, Early Detection, and Innovative Therapies for Ovarian Cancer
Guest: Dr. Robert Bast, Co-Founder of CA125 and Leading World Renowned Oncologist
You can also connect with us on social media: